热响应的甲基纤维素/氨酸-美沙胺水凝用于性结肠炎的向药物输送
Sheng-Nan Kuo1, Pei-Xhan Wu2, Shu-Ling Huang2,3
1Department of Chemical Engineering, National Tsing Hua University Hsinchu 30013 Taiwan Jenhuang@mx.nthu.edu.tw +886-3-5743051.
RSC advances
|May 2, 2025
概括
一种新的热反应性水凝,将氨酸-美沙胺 (HA-Me) 与甲基纤维素 (MC) 结合在一起,可以改善性结肠炎 (UC) 治疗. 这种有针对性的药物输送系统可以提高患者的保留,治愈和患者的服从性.
科学领域:
- 生物材料科学 生物材料科学
- 药物输送系统 药物输送系统
- 胃肠病学 胃肠病学
背景情况:
- 目前的性结肠炎 (UC) 治疗方法,如梅沙胺 (Me) 阴道,患有不良的结肠保留,全身副作用和患者遵守率低.
- 需要先进的药物输送平台来提高治疗疗效和患者在UC管理中的坚持.
研究的目的:
- 开发和表征一种热敏的水凝,用于针对性和持续的梅萨拉胺 (Me) 治疗性结肠炎 (UC).
- 评估水凝克服传统UC疗法的局限性的潜力.
主要方法:
- 通过核性添加-消除合成氨酸-美沙胺 (HA-Me) 结合物.
- 使用HA-Me结合物和甲基纤维素 (MC) 在不同度 (5-7 wt%) 中制备热反应性水凝.
- 使用FT-IR,1H-NMR进行表征,1H-NMR,用于确定较低的临界溶液温度 (LCST) 和凝性质的风湿学分析.
主要成果:
- 通过FT-IR和1H-NMR证实了HA-Me合物的成功合成,移植率为12.45%.
- 优化的水凝具有较低的临界溶液温度 (LCST) 36.7-37.7 °C,使化在体温下成为可能.
- 水凝显示增强了肠道保留,改善了药物释放,为伤口提供了保护性屏障,并表现出粘粘性质.
结论:
- 开发的甲基纤维素/氨酸-美沙胺 (MC/HA-Me) 水凝是针对性和持续性性结肠炎 (UC) 治疗的有希望的平台.
- 这种创新的水凝系统提高了药物的生物可用性,促进了伤口愈合,降低了再感染的风险,并提高了患者的合规性.
- 这项研究支持这种水凝在量身定制的治疗应用和UC治疗中的未来临床开发方面的潜力.
相关概念视频
01:29Drugs for Treatment of Ulcerative Colitis in IBD
102
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
102
01:21Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
86
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
86
01:29Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
100
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
100
01:17Drugs for Treatment of Diarrhea-Predominant IBS
117
Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
117
01:24Drugs for Peptic Ulcer Disease: Sucralfate as Mucosal Protective Agents
319
In the intricate landscape of the gastric lumen, excessive acid secretion disrupts the natural defense mechanisms, weakening the mucus-bicarbonate barrier. This vulnerability allows pepsin to infiltrate epithelial cells, digesting mucosal proteins and triggering erosion, leading to ulcer formation.
In this scenario, mucosal protective agents like sucralfate play an essential role. Sucralfate, a complex of sulfated sucrose and aluminum hydroxide, demonstrates its usefulness in acidic conditions,...
In this scenario, mucosal protective agents like sucralfate play an essential role. Sucralfate, a complex of sulfated sucrose and aluminum hydroxide, demonstrates its usefulness in acidic conditions,...
319
01:29Inflammatory Bowel Disease IV: Pharmacological Management
79
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
79